Jade Biosciences (JBIO) Operating Income (2020 - 2026)

Jade Biosciences has reported Operating Income for 7 years, with the latest figure at -$43.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 85.79% year-over-year to -$43.4 million; the trailing twelve-month figure through Mar 2026 stood at -$133.6 million (down 173.75% YoY), and the FY2025 full-year result was -$113.5 million, down 677.47% from the prior year.
• Operating Income for Q1 2026 stood at -$43.4 million, down from -$35.0 million in the prior quarter.
• The five-year high for Operating Income was $43.5 million in Q4 2023, with the low at -$43.4 million in Q1 2026.
• Historically, Operating Income has averaged -$13.7 million across 5 years, with a median of -$17.6 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Income jumped 421.19% — and 2025, when it tumbled 4608.14%.
• Jade Biosciences' Operating Income stood at $26.6 million in 2022, then jumped by 63.85% to $43.5 million in 2023, then slumped by 122.67% to -$9.9 million in 2024, then plunged by 254.54% to -$35.0 million in 2025, then slipped by 24.2% to -$43.4 million in 2026.
• The last three Operating Income figures came in at -$43.4 million (Q1 2026), -$35.0 million (Q4 2025), and -$27.4 million (Q3 2025), per Business Quant data.